Lowell Schmeltz is an Endocrinology/Metabolic physician affiliated with Oakland University. OpenAlex indexes 20 publications with 552 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
32255 Northwestern Hwy Ste 214
Farmington Hills, MI 48334
Telephone
248-855-5620Registry record last updated 30 May 2018.
Industry payments
55 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Lilly USA, LLCProgram year2025118 payments$85,020openpaymentsdata.cms.gov ↗
- GENZYME CORPORATIONProgram year202512 payments$38,394openpaymentsdata.cms.gov ↗
- SANOFI-AVENTIS U.S. LLCProgram year202524 payments$35,898openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
55.8%Insulin Analog22%Lantus Solostar31%Tresiba Flextouch U-10015%Novolog Flexpen10%Tresiba Flextouch U-2007%Humalog Kwikpen U-1006%Novolog5%Humalog4%Humalog Kwikpen U-2004%Basaglar Kwikpen U-1004%Fiasp Flextouch3%Toujeo Max Solostar3%Lantus3%Fiasp2%Lyumjev Kwikpen U-1002%Insulin Aspart Flexpen2%Part D<11 patientsGLP-1 receptor agonist17%Mounjaro82%Ozempic11%Trulicity8%Part D<11 patients+ 5 more classes in this area
Hormonal (systemic)
39.6%l-Thyroxine37.1%Levothyroxine Sodium86%Synthroid8%Levoxyl5%Unithroid2%Part D<11 patientsMineralocorticoids1%Fludrocortisone Acetate100%Part D<11 patients+ 2 more classes in this area
Cardiovascular
2.9%Statin1.7%Atorvastatin Calcium76%Simvastatin24%Part D<11 patientsAngiotensin receptor blocker (ARB)0.8%Losartan Potassium100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Analytical and clinical performance of the updated Elecsys Anti-TPO II assay for the detection of antibodies against thyroid peroxidase to aid in the diagnosis of autoimmune thyroid diseases
Clinical Chemistry and Laboratory Medicine (CCLM)
2026 - Predictors of Initial Response of Thyroid Nodules Treated With RFA, a Multi-Endocrinology Centers Experience From the United States
Journal of the Endocrine Society
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Alon Kahana, MD
Oakland University
Mitchell Cappell, MD
Oakland University
Thomas Schwann, MD
Oakland University
Laith Jamil, MD
Oakland University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”